Detail akcie Quantum Bio Rg-SB online

Business Summary: Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The Company has also licensed unbuzzd, a formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of quickly relieving individuals from the effects of alcohol consumption. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Quantum Biopharma Ltd revenues was not reported. Net loss increased from $9.5M to $23.1M. Higher net loss reflects Effective G/L on Derivatives - Hedging decrease from $31K (income) to $11.9M (expense), Share-based payments increase from $235K to $2.1M (expense), External research and development fees increase of 49% to $2.7M (expense).